Kei Daroo Health Technology

Keidaroo is an Iranian biotechnology company specializing in the development and production of high-tech biopharmaceuticals, particularly recombinant proteins and biosimilars. Founded in 2011 and headquartered in Tehran, the company focuses on providing affordable therapeutic solutions for complex diseases such as multiple sclerosis, osteoporosis, and various cancers. Their commercial portfolio includes products like Kei-Feron (interferon beta-1a) and Kei-G-CSF (filgrastim), manufactured in facilities that adhere to international Good Manufacturing Practice (GMP) standards. Keidaroo plays a significant role in the Middle Eastern pharmaceutical market by reducing reliance on imported biologics through local innovation and large-scale production. The company continues to expand its pipeline into new therapeutic areas, including hematology and endocrinology.